Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Injecting BPC-157 for Knee Pain: A Researcher’s Overview

Knee pain is a formidable adversary. It can sideline athletes, complicate daily life, and turn simple movements into grueling challenges. In the world of biotechnology and regenerative medicine, the search for effective solutions is relentless. This has brough

By Recovery & Performance Peptides Editorial Team

Knee pain is a formidable adversary. It can sideline athletes, complicate daily life, and turn simple movements into grueling challenges. In the world of biotechnology and regenerative medicine, the search for effective solutions is relentless. This has brought a particular peptide, BPC-157, into the spotlight. We've seen a dramatic surge in interest from the research community about its potential mechanisms, and with that comes a flood of questions—the most common one being about administration protocols, specifically: how to inject BPC 157 for knee pain in a research context.

Let's be clear from the start. Our work at Real Peptides is to supply the highest-purity, research-grade peptides for laboratory and pre-clinical study. We're obsessed with precision, from small-batch synthesis to exact amino-acid sequencing. This article is written from that perspective—as a resource for the scientific community. It is not medical advice. The information here is a consolidation of publicly available research data and our team's observations from working within this specialized field. It's designed to equip researchers with a foundational understanding of the methodologies being explored. The goal is always reproducible, reliable data, and that starts with impeccable technique.

First, A Refresher on BPC-157

Before diving into the 'how,' it's crucial to understand the 'what.' BPC-157, or Body Protection Compound 157, is a synthetic peptide chain composed of 15 amino acids. It's a partial sequence of a protein found in human gastric juice. A bit of an unlikely origin story, right? But its discovery opened up a fascinating area of study. Researchers became intrigued by its apparent cytoprotective and regenerative properties, observing its effects far beyond the digestive tract.

The primary mechanism that gets researchers excited is its role in angiogenesis—the formation of new blood vessels. Proper blood flow is a critical, non-negotiable element of tissue repair. When a tendon, ligament, or muscle is damaged, the body's ability to shuttle nutrients and growth factors to the site dictates the speed and quality of healing. Pre-clinical studies suggest BPC-157 may significantly upregulate this process. It's also been observed to have potent anti-inflammatory effects and to influence the nitric oxide (NO) system, further contributing to its potential in a therapeutic research model. We've found that researchers who grasp these underlying mechanisms are far better equipped to design effective study protocols.

The Bedrock of Good Research: Sourcing Your Compound

We can't stress this enough: the purity and integrity of your peptide will make or break your research. It's the variable that can render weeks or months of work completely invalid. The peptide market is, frankly, sprawling and inconsistent. You can find products of questionable origin, riddled with impurities or incorrect peptide sequences. This isn't just bad for data; it's a significant safety concern in any study.

Our entire operation at Real Peptides is built around solving this problem. We utilize small-batch synthesis to maintain stringent quality control, ensuring that what's on the label is precisely what's in the vial. Every batch of our BPC 157 Peptide is a testament to this commitment. For researchers, this means consistency. It means you can be confident that the effects you're observing are attributable to the compound itself, not some unknown contaminant. When you're investigating something as nuanced as tissue regeneration, you simply cannot afford to introduce confounding variables. Sourcing from a reputable, transparent supplier is the first and most important step in any serious research endeavor.

Systemic vs. Localized: Choosing an Administration Route

Now, this is where the conversation gets more technical. When planning a study on knee pain, the first major decision is whether to administer the peptide systemically or locally. Each approach has a different hypothesis behind it.

Systemic Administration: This typically involves a subcutaneous (SubQ) injection in a location away from the injury site, like the abdominal fat. The theory is that BPC-157, once in the bloodstream, travels throughout the body and exerts its healing effects wherever damage is present. It’s a broader, less targeted approach.

Localized Administration: This involves injecting the peptide as close to the site of injury as possible. For the knee, this could mean a subcutaneous injection into the skin/fat around the joint or, in more advanced protocols, an intramuscular (IM) injection into a nearby muscle. The hypothesis here is that concentrating the compound at the source of the problem will yield a more potent and rapid response.

Our experience shows that most researchers focusing on specific joint issues, like knee pain, gravitate toward localized administration. The logic is compelling: deliver the repair crew directly to the construction site. It's more efficient. However, the exact method—SubQ versus IM—is a subject of ongoing debate and depends heavily on the specific research model.

Here’s a breakdown of the considerations:

Location

Injected into the fatty layer just under the skin.

Injected directly into a muscle belly.

Absorption Rate

Slower, more sustained release into the bloodstream.

Faster absorption due to higher blood flow in muscle tissue.

Technical Skill

Relatively simple; requires pinching the skin.

More complex; requires knowledge of anatomy to avoid nerves and major blood vessels.

Common Tools

Short, fine-gauge insulin syringe (e.g., 29-31 gauge, 1/2 inch).

Slightly longer needle may be needed depending on muscle depth, but insulin syringes often suffice.

Application for Knee

Injected into a fold of skin near the knee joint (e.g., above, below, or to the side).

Injected into a supporting muscle like the vastus medialis or lateralis.

Primary Goal

Localized saturation of the area with a sustained release profile.

Rapid delivery to the muscle and surrounding tissues for immediate action.

For most pre-clinical research involving joint pain, localized subcutaneous injection offers a fantastic balance of targeted delivery and ease of administration. It's the method we see employed most frequently.

Assembling Your Toolkit: The Necessary Supplies

Proper research demands preparation. Walking into a lab session without the right tools is a recipe for contamination and inaccurate results. It's simple, really. Here’s the essential checklist:

Lyophilized BPC-157: The peptide comes as a delicate, freeze-dried powder in a sealed vial. Again, the quality here is paramount.

Bacteriostatic Water: This is not just sterile water. It contains 0.9% benzyl alcohol, which acts as a preservative, preventing bacterial growth after the vial has been reconstituted. Using anything else (like sterile water or saline) dramatically reduces the shelf-life and safety of your reconstituted peptide. We offer high-quality Bacteriostatic Water specifically for this purpose.

Insulin Syringes: For both reconstitution and administration, U-100 insulin syringes are the standard. They are marked in units, making precise measurement straightforward. A 29-31 gauge needle is typical—it’s very fine, minimizing discomfort and tissue disruption.

Alcohol Swabs: Sterility is a non-negotiable. You’ll need these to wipe the rubber stoppers of both the BPC-157 and bacteriostatic water vials, as well as the injection site itself.

Having these items organized and ready before you begin is a hallmark of professional lab conduct. It minimizes handling time and reduces the risk of error or contamination.

The Art of Reconstitution: A Precise, Step-by-Step Protocol

Reconstituting a lyophilized peptide is a delicate process. The peptide itself is a fragile chain of amino acids. Shaking it vigorously or using the wrong diluent can damage the molecule, rendering it ineffective. Here’s how our team recommends approaching it for maximum viability.

Step 1: Preparation is Everything.Wash your hands thoroughly. Lay out all your supplies on a clean, disinfected surface. Use an alcohol swab to vigorously clean the rubber stoppers on both your vial of BPC-157 and your vial of bacteriostatic water. Let them air dry for a moment.

Step 2: Drawing the Bacteriostatic Water.Take an insulin syringe and draw air into it, equivalent to the amount of water you plan to pull out (e.g., 1 mL or 100 units). Insert the needle into the bacteriostatic water vial and inject the air. This pressurizes the vial, making it easier to draw the liquid. Now, invert the vial and slowly pull back the plunger to draw your desired amount of water. Most researchers use 1 mL or 2 mL of water per 5 mg vial of BPC-157 for easy dosing calculations.

Step 3: The Gentle Mix.This is the critical part. Insert the needle of the water-filled syringe into the vial of BPC-157 powder. Angle the needle so the stream of water runs down the inside wall of the glass vial. Do not spray the water directly onto the powder clump. That's too aggressive. Inject the water slowly and gently.

Step 4: The Swirl, Never the Shake.Once all the water is in, the powder will begin to dissolve. To help it along, gently swirl the vial between your fingers or roll it in your palms. Never, ever shake it. You're not making a cocktail; you're preserving a delicate protein structure. Within a minute or two, the solution should be perfectly clear. If you see any cloudiness or floaters, it may be a sign of a low-purity product or improper reconstitution.

Step 5: Proper Storage.Once reconstituted, your BPC-157 is now active and must be stored in the refrigerator (not the freezer). It will typically remain stable for several weeks when refrigerated properly.

How to Inject BPC 157 for Knee Pain: Exploring Research Protocols

Alright, this is the core of the matter. Based on our review of available literature and discussions within the research community, protocols for knee-related studies primarily focus on localized subcutaneous injections.

The Subcutaneous (SubQ) Protocol for Knee Research

The goal is to deposit the peptide into the subcutaneous fat layer surrounding the knee joint, allowing it to saturate the local tissues—tendons, ligaments, and the joint capsule itself.

Site Selection: Identify a suitable injection site. This should be an area with a pinchable layer of skin and fat. Common sites for knee research are about one to two inches away from the most painful or damaged area. This could be to the left or right of the kneecap, or directly above or below it. Avoid injecting directly into a tendon or ligament itself. You're aiming for the tissue around the problem area.

Sterilization: Thoroughly clean the selected site with an alcohol swab and let it air dry. This is a simple step that prevents infection.

Drawing the Dose: Take your refrigerated, reconstituted BPC-157 vial. Clean the stopper again with a fresh alcohol swab. Using a new, sterile insulin syringe, draw your calculated dose. Let's say your protocol calls for 250 micrograms (mcg). If you mixed a 5 mg (5000 mcg) vial with 2 mL (200 units) of water, then each unit on the syringe contains 25 mcg of BPC-157. Therefore, a 250 mcg dose would be 10 units on the syringe. Double-check your math. Always.

The Injection: With one hand, gently pinch a one-to-two-inch fold of skin and fat at the injection site. With your other hand, hold the syringe like a dart. Insert the needle at a 45 to 90-degree angle into the pinched skin. The angle depends on how much subcutaneous fat is present; for most, a 90-degree angle is fine. The needle is so short it won't hit the muscle. Slowly depress the plunger to inject the solution. Wait a second or two, then smoothly withdraw the needle.

Post-Injection: You can gently press on the site with a clean cotton ball or gauze for a moment. There might be a tiny droplet of blood, which is normal. Do not massage the area, as this can disperse the peptide too quickly.

What About Intramuscular (IM)?Some advanced protocols explore IM injections into the muscles that stabilize the knee, such as the vastus medialis (the teardrop-shaped quad muscle on the inner side of the knee). The rationale is that improving the health of these supporting structures can alleviate stress on the joint. This is a more complex technique that requires a solid understanding of anatomy to perform safely and effectively in a research setting. For most studies on direct knee joint pathology, localized SubQ is the preferred, and frankly, simpler method.

Dosing, Frequency, and Synergy in Research Models

Dosing is one of the most debated aspects of peptide research. Most pre-clinical data is derived from animal studies, typically using a dose range of 1-10 mcg per kilogram of body weight. For a human-equivalent research model, this often translates to a total daily dose of 250-500 mcg.

Frequency is another key variable. Some protocols utilize a single daily injection, while others split the total dose into two smaller injections (e.g., 250 mcg in the morning and 250 mcg in the evening) to maintain more stable levels of the peptide in the local tissue. The optimal approach is still a subject of active investigation.

Furthermore, researchers are increasingly exploring peptide synergies. BPC-157 is often studied alongside another regenerative peptide, TB-500 (a synthetic version of Thymosin Beta-4). While BPC-157 is often seen as a master of localized repair and angiogenesis, TB-500 is thought to have more systemic effects, reducing inflammation, improving flexibility, and promoting healing on a broader scale. Our Wolverine Peptide Stack, which combines both, was developed in response to this growing area of research, providing a convenient option for studies looking at these synergistic effects. Investigating these combinations allows for a more comprehensive approach to understanding tissue regeneration.

Ultimately, the success of any research project is built on a foundation of quality, precision, and adherence to sterile, methodical protocols. From sourcing the purest compounds available—a mission that drives everything we do—to meticulously executing each step of the administration process, every detail matters. The potential of peptides like BPC-157 is vast, and it’s through this rigorous, scientific approach that we’ll unlock it. As you design your next study, remember that the quality of your inputs dictates the quality of your outcomes. You can explore our full collection of high-purity peptides to find the right compounds for your work. Don't hesitate to Get Started Today.

Frequently Asked Questions

A subcutaneous (SubQ) injection delivers the peptide into the fatty layer just beneath the skin for slower, more sustained absorption. An intramuscular (IM) injection goes directly into the muscle, resulting in faster absorption. For localized knee research, SubQ near the joint is most common.

When properly reconstituted with bacteriostatic water and stored in a refrigerator (around 2-8°C or 36-46°F), BPC-157 typically remains stable and potent for at least four weeks. Never freeze a reconstituted peptide.

Bacteriostatic (BAC) water contains 0.9% benzyl alcohol, which acts as a preservative to prevent bacterial growth in the multi-use vial. Using sterile water or saline significantly shortens the peptide’s safe-to-use lifespan to just 24-48 hours.

Our team strongly advises against this. While technically possible, pre-loading syringes increases the risk of contamination and potential degradation of the peptide, as it’s no longer in a sterile, sealed vial. It’s best practice to draw each dose immediately before administration.

There is no definitive scientific consensus on optimal timing. Some research protocols favor morning administration to align with the body’s natural healing cycles, while others split the dose. Consistency in timing is the most important factor for reliable study data.

Both are regenerative peptides, but they have different proposed mechanisms. BPC-157 is often studied for its potent localized healing and angiogenesis effects. TB-500 is thought to have more systemic actions, reducing inflammation and improving cellular migration across the entire body.

Lyophilization is a freeze-drying process that removes water from the peptide, rendering it a stable powder for shipping and storage. This process preserves the peptide’s delicate structure until it’s ready to be reconstituted for research.

First, know your total peptide amount (e.g., 5mg = 5000mcg) and the volume of water used (e.g., 2mL = 200 units on an insulin syringe). Divide the total mcg by the total units (5000mcg / 200 units = 25mcg per unit). Then, divide your desired dose (e.g., 250mcg) by the mcg/unit value (250 / 25 = 10 units).

Yes, it is good practice within a research protocol to rotate injection sites. Using the exact same spot repeatedly can cause localized irritation or tissue buildup. Rotating sites around the knee joint ensures better absorption and minimizes potential skin issues.

BPC-157 is stable in gastric acid, which is unique for a peptide. While some research explores oral administration, particularly for gut-related issues, injectable routes are considered far more bioavailable for addressing musculoskeletal injuries like knee pain.

A properly reconstituted, high-purity peptide solution should be perfectly clear. If it appears cloudy or has visible particles, it could indicate contamination, improper reconstitution, or a low-quality product. It should not be used in your research.

Peptides are long, fragile chains of amino acids. Shaking the vial can physically break these chains apart, a process called shearing, which destroys the molecule and renders it ineffective. Gentle swirling is all that’s needed to dissolve the powder while preserving its integrity.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Frequency Options

Micro-dosing protocols vary in administration frequency. The short half-life of BPC-157 (less than 30 minutes) suggests frequent dosing might optimize tissue levels, yet the peptide initiates cellular processes that continue after clearance. Several approaches work effectively: Once Daily Protocol: A single morning dose of 0.1 to 0.15 mg provides simplicity and good results for most chronic conditions. This approach minimizes injection frequency while maintaining therapeutic benefit. Twice Daily Protocol: Splitting the daily dose into morning and evening administrations (0.05 to 0.075 mg each) maintains more consistent tissue levels. Some individuals report better results with this approach, particularly for GI conditions. Five Days On, Two Days Off: This cycling pattern within each week may help maintain receptor sensitivity during extended protocols. The weekend break allows receptor resensitization while the consistent weekday dosing provides therapeutic benefit. BPC-157 does not develop traditional tolerance since it operates non-hormonally and does not suppress natural production. Unlike hormonal compounds, no post-cycle therapy is required and no rebound effects occur when discontinuing use.
STORAGE

Reconstitution, Storage, and Preparation: Where Most Timing Failures Occur

BPC-157 is sold as lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water before injection. The peptide is stable as a powder at −20°C for 12–18 months, but once reconstituted, degradation begins immediately. A reconstituted vial stored at 2–8°C (refrigerated) retains full potency for approximately 28 days. After that, peptide bond hydrolysis reduces bioavailability by 15–30% per week. Here's the mistake that eliminates peptide efficacy before timing ever matters: reconstituting the entire vial at once when you only need 7–10 days of doses. If you're dosing 250 mcg twice daily and your vial contains 5 mg total, that's a 10-day supply. Reconstituting the full vial means the last doses are 3–4 weeks old. Well past the stability window. Instead, reconstitute only what you'll use within 14 days and store the remaining lyophilized powder at −20°C. Bacteriostatic water (0.9% benzyl alcohol) extends reconstituted peptide stability slightly compared to sterile water, but it does not prevent peptide degradation. It prevents bacterial growth. Temperature excursions above 8°C cause irreversible structural changes to the peptide chain. If a reconstituted vial sits at room temperature for more than 2–3 hours (common during travel or forgotten on a counter), assume 20–40% potency loss. No amount of optimal timing compensates for degraded peptide.
02

Question drills

Open a question for its connected answer.

01What If BPC-157 Improves My Symptoms But Breath Tests Stay Positive?+

Symptom improvement without bacterial eradication suggests the peptide is addressing secondary pathology. Likely intestinal permeability and inflammation. While bacterial load remains elevated. This scenario appears in patients using prokinetics or low-FODMAP diets: symptoms abate because fermentable substrate is reduced or motility improves, but bacterial colonization persists. If BPC-157 studied SIBO applications show this pattern in your case, it indicates the peptide is functioning as a mucosal healing agent rather than an antimicrobial. You'd still need rifaximin, herbal antimicrobials, or elemental diet intervention to normalize breath testing.

SOURCE / realpeptides.co ↗
02What If the Research Focus Is Purely Angiogenesis?+

BPC-157 comparative studies position it as the strongest standalone angiogenic peptide outside of VEGF itself. In vitro endothelial proliferation assays show BPC-157 inducing proliferation at 85% of VEGF's magnitude at equimolar doses, compared to TB-500 at 22%. For ischemia models, wound healing studies, or vascular regeneration research, BPC-157 demonstrates direct angiogenic signaling that collagen peptides and most repair peptides lack entirely.

SOURCE / realpeptides.co ↗
03What If Peptide Purity Is Below 95% — Does It Affect Pharmacological Activity?+

Yes, significantly. BPC-157 pharmacology studies rely on precise amino acid sequencing. A single substitution or deletion in the 15-amino-acid chain alters receptor interactions and signaling pathway activation. Peptides below 95% purity often contain truncated sequences, oxidized amino acids, or synthesis by-products that compete for binding sites without producing therapeutic effects. HPLC (high-performance liquid chromatography) and mass spectrometry verification are non-negotiable for reproducible research outcomes. If your peptide supplier can't provide third-party purity certificates, your study results become unreliable.

SOURCE / realpeptides.co ↗
04What If Biofilm Formation Is Already Established?+

Increase LL-37 dosing frequency to maintain sustained local concentration. Mature biofilms (>72 hours old) require continuous peptide exposure to degrade EPS and penetrate bacterial clusters. Research protocols use twice-daily LL-37 administration (10 mg per dose) rather than once-daily for established biofilm infections. BPC-157 remains at standard dosing (400 mcg daily) because its vascular effects are cumulative, not concentration-dependent. Biofilm clearance in animal models takes 14–21 days under this protocol. Significantly longer than planktonic bacterial infections.

SOURCE / realpeptides.co ↗
05What If I Mix BPC-157 Incorrectly—Does Storage Temperature Matter?+

Yes—dramatically. Lyophilized (freeze-dried) BPC-157 is stable at room temperature for months, but once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 25°C cause irreversible peptide bond cleavage—the resulting fragments are biologically inactive. We've reviewed preparation protocols across research labs: the most common error is leaving reconstituted vials at room temperature during multi-dose use. Each time you draw a dose, return the vial to refrigeration immediately.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

BPC-157 Studied Concussion Recovery — Research Insights

Research from the University of Zagreb published in 2014 demonstrated that BPC-157 (Body Protection Compound-157) reduced brain edema by 42% and improved motor coordination recovery timelines by 35% in rodent models of traumatic brain injury compared to saline controls. The peptide. A synthetic derivative of a gastric protective protein. Crosses the blood-brain barrier and appears to modulate neuroinflammation through pathways most existing concussion therapies ignore entirely. Our team has analyzed the full body of preclinical evidence on BPC-157 studied concussion recovery, and the mechanistic data is more compelling than the marketing claims suggest. But also narrower in scope than most supplement retailers acknowledge. We've guided researchers and clinicians through peptide literature reviews for over a decade. The gap between what the animal models show and what human application looks like comes down to three variables: dosage translation, administration timing relative to injury, and the fact that concussion isn't one uniform pathology. It's a cascade with multiple inflection points. How does BPC-157 studied concussion recovery work at the molecular level? BPC-157 studied concussion recovery targets neuroinflammation by stabilizing the blood-brain barrier and modulating VEGF (vascular endothelial growth factor) receptor activity, which accelerates angiogenesis and reduces secondary injury cascades that follow the initial trauma. Preclinical studies show 40–60% reductions in inflammatory cytokines (TNF-α, IL-6) within 72 hours post-injury when administered immediately after TBI. This matters because the secondary injury phase. The 48–96 hour window where excitotoxicity and oxidative stress compound initial damage. Is where most long-term disability originates, and standard clinical protocols have limited tools to intervene during this period. Most concussion content stops at 'reduces inflammation'. That's insufficient. BPC-157 studied concussion recovery operates through a mechanism fundamentally different from NSAIDs or corticosteroids. The peptide doesn't suppress cyclooxygenase enzymes or glucocorticoid receptors. Instead, it activates the FAK-paxillin pathway, which promotes actin cytoskeleton reorganization in damaged neurons. Essentially helping axons rebuild their structural integrity after shearing forces disrupt microtubule networks. The Zagreb research demonstrated this through electron microscopy showing restored synaptic density in hippocampal CA1 regions 14 days post-injury, a result that spontaneous recovery doesn't achieve until 28–35 days. This article covers the specific mechanisms at work, the dosage ranges tested in animal models, what the human translation challenges are, and why timing of administration matters more than dose escalation.

RESEARCH

BPC-157: what scientific studies reveal about its effects

BPC-157 is derived from a protective protein found in the stomach but is considered "synthetic" since this peptide does not exist by itself in nature. It’s touted for a wide variety of reasons and talked about for both nootropic (brain boosting) and ergogenic (performance enhancing) purposes. And based on all the studies published so far, BPC-157 is a surprisingly good regenerative agent. What is BPC-157 thought to aid? Joint Health and Rejuvenation Fibroblasts are a specialized type of cell found in connective tissues. These cells are involved in the creation of collagen. The use of BPC-157 is thought to speed up the growth and spread of fibroblasts and to increase rates of oxidative resistance. In addition to its effects upon fibroblast production. It also affects F-actin formation (which is involved in the spreading of fibroblasts). The peptide has also been successfully used to increase the rate of collagen reformation following surgery. The above findings go a long way to explaining how the administration of BPC-157 is able to promote healthy tendon and ligament healing. Accelerates Bone Healing As gastrectomy is related to derogatory bone conditions such as osteoporosis it is no surprise that the use of BPC-157, with its well-known fracture and wound healing aspects, is associated with improved bone health. Research using rabbits has shown that the peptide is able to significantly improve healing related to osteoperiosteal bone defects over a six-week (1.5 months) period, especially following an autologous cortical graft or the local application of bone marrow. Furthermore, the number of animals that healed was much greater in the experimental than what occurred in the control group. So it seems that the use of BPC-157 can both increase the rate and the frequency of recovery from bone damage. Although the above experiments took place in lagomorphs the authors are very excited about its potential use in the management of bone-related impairments that may occur in human patients. Protects against intestinal damage One of the most exciting aspects of BPC-157 is its potential for protecting the intestines from inflammatory damage. When toxins were given to rats to mimic the effect of intestinal inflammation, the use of this peptide reduced the number of visual markers known to be associated with intestinal gut damage. The direct injections of BPC-157 into specific parts of rats is thought to help repair intestines through impacting nitric oxide signalling. It can also help to overcome problems related to short gut (Short Bowel Syndrome: SBS). This condition often leads to malnutrition and dehydration because of increased incidence of diarrhoea. The use of this peptide can help to make this problematic condition much better. It is also thought to be able to help repair damaged tissues caused by inflammatory bowel disease (IBD). Compulsion This peptide is known to impact dopamine levels, though there is as yet no evidence for the direct binding of dopamine receptors. It is therefore thought that its main action with regards to dopaminergic neurotransmission is likely to be through the antagonism of dopamine itself, and this interaction is thought to reduce the effects of amphetamine on compulsive behaviours. Protect against gut damage caused by NSAIDs Although they act great as painkillers one of the big problems with NSAIDs is that they can be toxic to the gut, this frequently leads to ulcers and an irritation of the bowels. BPC-157 is able to act as an anti-ulcer peptidergic agent and has been put forward as an NSAIDs antidote as it is beneficial against damage caused by mediated lesions in the gastrointestinal tract, brain, and the liver, and is able to counteract symptoms associated with the taking of aspirins, such as bleeding. The present research suggests that BPC-157 does not have toxic effects itself and is thus thought likely to have very high safety in its use against gastric damage caused by NSAIDs. Neuroprotection As BPC-157 is able to reduce cell damage in the hippocampus of rats it very likely confers neuroprotective effects. It can help protect the brain tissue from damage when rats are given cuprizone (a toxin that scientists use to mimic the effects of schizophrenia and multiple sclerosis) it is thought that actual protection of the nerves may actually occur through intestinal processes. WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Sever, M., et al. (2019). The stable gastric pentadecapeptide BPC 157 counteracts adjuvant arthritis in rats. Journal of Orthopaedic Research, 37(3), 582–593. PubMed Vukojević, J., et al. (2017). Stable gastric pentadecapeptide BPC 157 enhances the healing of transected rat Achilles tendon. Journal of Orthopaedic Research, 35(6), 1301–1310. PubMed Sikiric, P., et al. (2016). Stable gastric pentadecapeptide BPC 157 therapy for primary myotendinous junction transection, colitis, and intestinal anastomosis healing. World Journal of Gastroenterology, 22(26), 7373–7384. PubMed Central Sikiric, P., et al. (2018). BPC 157 and standard angiogenic growth factors. Vascular Pharmacology, 111, 57–65. PubMed Sikiric, P., et al. (2017). BPC 157 and the central nervous system. Current Neuropharmacology, 15(6), 857–865. PubMed Central

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles